Submissions

Author Guidelines

Author Submission Guidelines – ASIDE Oncology

Submission Invitation

Authors are invited to submit their work to ASIDE Oncology. All submissions will be evaluated by an editor to determine if they align with the aims and scope of the journal. Submissions deemed a good fit will be sent for peer review before a final decision is made regarding acceptance or rejection.

Before submitting, authors are responsible for securing permission for all material included in their manuscript, such as images, documents, and datasets. All listed authors must consent to be identified as authors. Where relevant, research involving humans or animals must have received appropriate ethics committee approval, following the legal requirements of the study’s country.

Editors may desk-reject submissions that do not meet minimum quality standards. Please ensure your study design and research argument are well-structured and clearly articulated. The title should be concise, and the abstract must stand alone. Following these standards increases the likelihood that reviewers will agree to assess your work. When you are confident your submission meets these requirements, please follow the checklist below to prepare your manuscript.

1. REQUIRED FILES

Each submission to ASIDE Oncology must include:

• Title Page File (Word document)

• Main Manuscript File (blinded)

• Tables File(s)

• Figures (PowerPoint format)

• Manuscript Highlights File

• Required Documentation (depending on study type)

2. TITLE PAGE FILE SPECIFICATIONS

1. Manuscript Title

   • Clear, concise, and reflective of oncology content

   • Avoid abbreviations unless standard in oncology

2. Author Information

   • Full names with academic degrees

   • Institutional affiliations and full addresses

   • Email addresses for all authors

   • ORCID identifier (mandatory for corresponding author, optional for others)

3. Corresponding Author Details

   • Complete contact information, including institutional address, telephone, email, and ORCID ID (mandatory)

3. MAIN MANUSCRIPT STRUCTURE

1. Blinding Requirements

   • Remove all author identifiers

   • Eliminate self-referential statements

2. Required Sections

   • Abstract (max 250 words): Structured (Introduction, Methods, Results, Conclusions). No undefined abbreviations or citations.

   • Keywords: 3-6 relevant to oncology

   • Main Text: Introduction, Methods, Results, Discussion, Conclusions

   • Declarations:

     • Conflicts of Interest (state “N/A” if none)

     • Ethics Approval/IRB Statement (state “N/A” if not applicable)

     • Informed Consent Statement (state “N/A” if not applicable)

     • Clinical Trial Registration (state “N/A” if not applicable)

     • Funding Sources (state “N/A” if not applicable)

     • Acknowledgements (state “N/A” if not applicable)

     • Data Availability Statement (explain if not applicable)

     • Large-Language Model (LLM) – Generative AI Use Statement (if used; otherwise, state “N/A”)
       Example: “We have employed an advanced Large Language Model (LLM) to enhance and refine the English-language writing. This process focused solely on improving the text’s clarity and style, without generating or adding any new information to the content.”

     • Authors’ Contribution Statement (mandatory, using CRediT taxonomy; e.g., Conceptualization, Methodology, Software, etc.)

   • References: Vancouver style, all references must include DOI and PMCID/PMID if available, or URL if not. List references in the order they appear in the text.

4. FIGURES AND TABLES SPECIFICATIONS

1. Figures

   • Format: PowerPoint files only (required)

   • Dimensions: 1200x1200 pixels minimum, 3000x3000 pixels maximum

   • Resolution: Minimum 300 dpi

   • One figure per slide

   • Legend: Place below the figure; define abbreviations, explain symbols/markers, include scale bars (if applicable), use color only with scientific justification

2. Tables

   • Format: Word document

   • Structure: Clear, descriptive titles, no vertical lines, consistent formatting

   • Legend: Place below the table; define abbreviations, explain symbols/statistics, add notes if necessary

5. REQUIRED DOCUMENTATION BY MANUSCRIPT TYPE

• Editorial, Review, Frontier, Field of Vision, Minireview, Letter to The Editor, Correction, Retraction Note: None required.

• Basic Science / Pre-Clinical Study:

  • Clinical Trial Registration (recommended)

  • Institutional Animal Care and Use Committee statement (for animal studies)

  • ARRIVE Guidelines (for animal research)

• Retrospective Study, Clinical Practice Study:

  • Clinical Trial Registration

  • Signed Informed Consent (for human research)

• Case Control, Observational, Retrospective Cohort Study:

  • Clinical Trial Registration

  • Signed Informed Consent

  • STROBE Statement

• Clinical Trial/Prospective/Randomized Controlled Trial:

  • Clinical Trial Registration

  • Signed Informed Consent

  • CONSORT 2010 Statement

• Systematic Review, Meta-Analysis:

  • PRISMA 2020 Checklist

• Case Report:

  • Signed Consent for Treatment

  • CARE Checklist

6. REVISION REQUIREMENTS

• Revised Manuscript Versions:

  • Version 1: Changes highlighted in yellow

  • Version 2: Clean copy

• Response to Reviewers:

  • Point-by-point, with page/line numbers for changes and justification for declined suggestions

COMPLIANCE STATEMENT

Manuscripts not conforming to these specifications will be returned without review. Authors must verify compliance with all requirements before submission. The editorial office reserves the right to reject manuscripts not meeting these standards at any stage.

Author Charges Policy

• No Charges: ASIDE Oncology does not impose any fees at any stage of the manuscript process, including:

  • Submission fees

  • Editorial processing charges

  • Article processing charges (APCs)

  • Page or color charges

• Fee Waivers: Not applicable, as there are no charges.

• Withdrawal Charges: No withdrawal fees. Authors are encouraged to submit only when ready for review to avoid unnecessary processing.

Plagiarism Policy

• Commitment to Originality: All submissions are screened for plagiarism to uphold the highest standards of publication ethics and integrity.

• Checking Process: ASIDE Oncology uses advanced detection tools (e.g., iThenticate, Turnitin). Authors should verify originality before submitting.

• Acceptance Criteria: A similarity score below 20% is required for publication. Manuscripts above this threshold may be returned for revision or rejected.

ASIDE Crossmark Policy

• Permanency of Content: All ASIDE Oncology articles receive a DOI and are permanently published, regardless of peer review outcome.

• Archiving: All content is permanently archived, including articles not yet peer-reviewed. Peer-reviewed articles are archived in databases.

• Content Updates: The Crossmark logo on each article links to its current status and the latest version, providing additional information as needed.

Correction to an Article

• Corrections (Errata) are published to alert readers to post-publication errors.

Retraction

• Articles may be retracted for reasons including honest error, research misconduct, duplicate publication, fraudulent data, plagiarism, or unethical research.

• Retraction notices will clearly state the reason, who initiated the retraction, and will be linked to the original article (which will be marked as retracted).

• Articles are retracted only at the author’s request or by the publisher following investigation.

• Content may be removed only for legal reasons (e.g., defamatory or court-ordered removal), with bibliographic details and explanation retained.

Editorial Note

• If there is an unresolved issue or ongoing investigation, an Editorial Note may be posted to alert readers.

For more details, please contact the editorial office at [email protected].